Oct 28, 2026 · 42 min
Lilly targets copycat retatrutide as families seek accountability
Alex Pretti's Parents Demand Justice & Copycat Weight Loss Drugs
The episode connects two accountability gaps: a family seeking information after a federal shooting and regulators confronting an expanding market for unapproved drugs.
- 1The Crime Victims Rights Act may offer Alex Pretti’s family information and consultation rights, though its application before charges remains uncertain.
- 2Eli Lilly is using state unfair-competition claims against vendors selling unapproved retatrutide, a strategy that may outperform private federal-law enforcement efforts.
- 3Limited FDA enforcement and strong consumer demand have helped research-use-only peptide sellers operate in a legally contested market.
Don't miss
Leon Fresco explains why Eli Lilly may have a stronger case under state unfair-competition law than under federal drug law.
The brief
Alex Pretti’s parents are seeking evidence and accountability after federal agents killed their son during immigration protests in Minnesota, while authorities have provided few answers.
Leon Fresco explains how the Crime Victims Rights Act could give the family information and consultation rights, but says its reach before charges remains unsettled.
The prospects for charges against the agents remain unclear: the investigation’s progress is disputed, judicial review may be possible, and future prosecutors could face applicable statutes of limitations.
The episode then turns to retatrutide, Eli Lilly’s unapproved weight-loss drug, whose copycat versions are sold online and through wellness clinics under research-use-only labels.
Fresco argues Lilly’s state-law unfair-competition lawsuits may be stronger than private attempts to enforce federal drug laws, as FDA capacity struggles to match consumer demand.
The dispute also reaches beyond vendors: Lilly is preparing to defend a potential blockbuster while contesting whether retatrutide should be treated as a drug or biologic.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.